Evidence map›Paper›PMID 37943422›Full record

ArticleJournal of nephrology2024

Single-dose antithymocyte globulin in standard immunological risk kidney transplant recipients: efficacy and kinetics of peripheral blood CD3

Fabiani P Machado, Nicole Rauber, Alessandra R Vicari, Andrea C Bauer, Roberto C Manfro

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fabiani P MachadoUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID 0000-0002-6308-0891
Nicole RauberUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID 0000-0002-5061-2633
Alessandra R VicariUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID 0000-0003-3325-152X
Andrea C BauerUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID 0000-0002-5041-4792
Roberto C ManfroUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. rmanfro@hcpa.edu.br.ORCID 0000-0001-8324-3734
Universidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolyclonal anti-T cell antibodies (ATG or thymoglobulin®) are used as induction therapy in kidney transplant recipients. This study evaluates the safety, efficacy, and CD3

methodsThe trial included two cohorts of kidney transplant recipients that were followed for one year. The study group, including standard immunological risk recipients, received one 3 mg/kg dose of ATG. The comparator group, including standard and high immunological risk kidney transplant recipients, received a fractionated dose regimen (up to four 1.5 mg/kg doses). Patient and graft outcomes and the kinetics of CD3

resultsOne hundred kidney transplant recipients were included in each group. The one-year incidence of treated acute rejection, and patient and graft survival did not differ between groups. Bacterial infections were significantly more frequent in fractionated-dose group patients (66% versus 5%; P = 0.0001). At one-year follow-up, there was no difference in the incidence of cytomegalovirus infection (P = 0.152) or malignancies (P = 0.312). CD3

conclusionBoth regimens resulted in low rejection rates and equivalent survival. The single and reduced dose regimen protects from the occurrence of bacterial infections. CD3

Indexed as

Antilymphocyte SerumCD3 ComplexGraft RejectionGraft SurvivalImmunosuppressive AgentsKidney TransplantationT-LymphocytesAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsTime FactorsAntilymphocyte SerumCD3 ComplexImmunosuppressive AgentsthymoglobulinAntibody induction therapyAnti-thymocyte globulinCD3+ T lymphocyteKidney transplantationModulation

Identifiers

PMID37943422
OpenAlexW4388531921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.